Puma Biotechnology Initiates Phase III Trial of PB272 (Neratinib) in HER2-Positive Metastatic Breast Cancer Patients

Published: Jun 07, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE:PBYI), a development stage biopharmaceutical company, announced the initiation of its Phase III clinical trial of the Company's lead drug candidate PB272 (neratinib) in patients with HER2-positive metastatic breast cancer who have failed two or more prior treatments (third-line disease).

Help employers find you! Check out all the jobs and post your resume.

Back to news